Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 172

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Clinicopathological and protein characterization of BRAF‐ and K‐RAS‐mutated colorectal cancer and implications for prognosis

Open access
Zlobec, Inti, Bihl, Michel P., Schwarb, Heike, Terracciano, Luigi, Lugli, Alessandro·2010·International Journal of Cancer

Abstract

Recent evidence highlights the potential prognostic and predictive value of BRAF and K‐RAS gene alterations in patients with colorectal cancer. However, a comprehensive evaluation of BRAF and K‐RAS mutations and their specific clinicopathological features, histomorphological presentation and effect on protein expression have not been systematically analyzed. The aim of this study was to characterize the clinicopathological, histomorphological and protein expression profiles of BRAF‐ and K‐RAS‐mutated colorectal cancers and determine their impact on patient survival. Molecular analysis for microsatellite instability (MSI), K‐RAS and BRAF was carried out on paraffin‐embedded samples from 404 patients with primary colorectal cancer. Using tissue microarrays, 36 tumor‐associated and 14 lymphocyte/inflammatory‐associated markers were evaluated by immunohistochemistry. BRAF mutation was associated with right‐sided tumor location (p < 0.001), higher tumor grade (p = 0.029), absence of peritumoral lymphocytic inflammation (p = 0.026) and MSI‐H (p < 0.001). In right‐sided tumors, loss of CDX2 expression was observed in 23 of 24 cases (95.8%). BRAF mutation was a poor prognostic indicator in patients with right‐sided disease (p = 0.01). This result was maintained in multivariable analysis (p < 0.001; HR = 2.82; 95% CI: 1.5–5.5) with pT, pN and vascular invasion and independent of CDX2 expression. K‐RAS mutation, in contrast, was not associated with any of the features analyzed. BRAF gene mutation is an adverse prognostic factor in right‐sided colon cancer patients independent of MSI status and, moreover, in patients with lymph node‐negative disease. These results indicate that molecular analysis for BRAF may be a useful biomarker for identifying patients with right‐sided colon cancer with poor outcome who may benefit from a more individualized course of therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ijc.25042

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 172

Metadata

Authors
Zlobec, I., Bihl, M. P., Schwarb, H., Terracciano, L., & Lugli, A.
Venue
International Journal of Cancer
Publisher
Wiley
Published
2010-02
Volume
127
Issue
2
Pages
367-380
ISSN
  • 0020-7136 (ISSN-L)
  • 1097-0215
OpenAlex
W2053652750
Cited by
172
References
2
FWCI
8.26
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinicopathological and protein characterization of BRAF‐ and K‐RAS‐mutated colorectal cancer and implications for prognosis. https://app.cochat.ai/papers/10.1002/ijc.25042
The paper
Zlobec, I., Bihl, M. P., Schwarb, H., Terracciano, L., & Lugli, A. (2010). Clinicopathological and protein characterization of BRAF‐ and K‐RAS‐mutated colorectal cancer and implications for prognosis. International Journal of Cancer. https://doi.org/10.1002/ijc.25042

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.